ArticleBMC complementary medicine and therapies2025
The potential of probiotic derivatives of Bacillus coagulans Hammer on induction of apoptosis in colorectal adenocarcinoma cell line in vitro.
Article in BMC complementary medicine and therapies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Characterization and Antifungal Efficacy of NJ-62 Protein from Weizmannia coagulans CGMCC 9951 against Ceratocystis fimbriata.Probiotics and antimicrobial proteins · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundColorectal cancer (CRC) remains as one of the leading causes of human morbidity and mortality worldwide. Dysbiosis in the structure of the gut microbiota resulting in increased abundance of harmful bacteria and decreased beneficial bacteria has been frequently associated with CRC development. Recently, probiotics and their derivatives have received great attention as anticancer agents for prevention and treatment of various cancers. This study aimed to assess the potential effects of probiotic Bacillus coagulans Hammer and its derivatives on induction of apoptosis in human colon adenocarcinoma cell lines in vitro.
methodsCell viability of HT-29 and Caco-2 cells was examined by MTT assay after exposure to varying concentrations of pasteurized and UV-killed B. coagulans Hammer, its extracellular vesicles (EVs), and cell-free supernatant (CFS). The apoptotic effects of different B. coagulans Hammer derivatives on HT-29 and Caco-2 cells were determined by analyzing the expression level of apoptosis-related genes (Bad, Bax, Bcl-2, Caspase-3, Caspase-9) using RT-qPCR assay. Annexin V-FITC/PI flow cytometry was performed to assess apoptosis. Protein expression of Bax and Bcl-2 was measured by Western blotting.
resultsHigh concentrations of B. coagulans Hammer derivatives significantly (P < 0.05) reduced viability of HT-29 and Caco-2 cells compared to untreated control. The results of RT-qPCR assay showed significant decrease in the expression level of antiapoptotic gene Bcl-2, and notable increase in the expression level of proapoptotic genes Bax, Bad, Caspase-3, and Caspase-9 in HT-29 and Caco-2 cells by B. coagulans Hammer derivatives. Flow cytometry demonstrated a high percentage of apoptotic HT-29 cells compared to untreated cells after exposure to B. coagulans Hammer derivatives. Western blotting analysis confirmed that treatment with EVs, UV-killed cells, and CFS significantly decreased Bcl-2 expression, and increased Bax expression in HT-29 cells.
conclusionsOur findings suggest that derivatives of probiotic B. coagulans Hammer can exert anticancer activity by induction of apoptosis in colon cancer HT-29 and Caco-2 cells. Further investigations are required to validate the safety and efficacy of B. coagulans Hammer derivatives in CRC prevention and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.